Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...
The agency’s new guidelines are created to eliminate pharmaceutical company practices that minimize or distract consumers ...
Investor's Business Daily on MSN4h
Stock Market Today: Chevron Breaks Out, But Biotechs Struggle As Eli Lilly Looks Like Short-Sale Play; Will American Airlines Break Out? (Live Coverage)Investors continued to see multiple shades of light red as biotechs continued to struggle in the wake of the postelection ...
A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing ...
Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.
Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation and aggregation into neurofibrillary tangles (right). [Courtesy of Eli ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...
Three stocks that have not only been around for a century but have also been paying dividends for that long are Coca-Cola ...
The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback